Glendon French

Part of Sanofi, Applied Immune Sciences, Inc. is a surgical and medical instruments company. The company is based in Menlo Park, CA. The company was founded by Thomas B. Okarma. Applied Immune Sciences was acquired by Rhone-Poulenc Rorer, Inc. on November 28, 1995 for $84.40 million.

C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ.

Part of CVS Health Corp., Pacific Physician Services, Inc. is a company that provides managed pre-paid health care. The company is based in Redlands, CA. Pacific Physician Services was acquired by Caremark Rx, Inc. on February 22, 1996 for $332 million.

AMO Manufacturing USA LLC engages in the design, develop and manufacture of excimer refractive surgical systems. It is designed to re-contour the front surface of the cornea of the human eye. The company was founded in 1988 and is headquartered in Santa Clara, CA.

Aramark Services, Inc. provides managed and professional services to business, educational, healthcare, governmental institutions, sports, entertainment and recreational facilities. It offers both rental and direct marketing services. The company was founded by Davre Davidson, Henry Davidson, and William Fishman in 1959 and is headquartered in Philadelphia, PA.

Asthmatx, Inc. develops catheter-based outpatient procedure that provides asthma control for adult severe asthma patients. The company was founded in 2003 and is headquartered in Sunnyvale, CA.

Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients.